ClinicalTrials.gg
CompletedNCT04729621Updated Oct 1, 2026Results posted

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

A Phase 3 interventional study of TVB-009 and Prolia® in Osteoporosis, Postmenopausal, sponsored by Teva Pharmaceuticals USA. Completed at 78 sites in 10 countries. Open to female participants aged 60 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Teva Pharmaceuticals USA (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

How we know

Updated Oct 1, 20269 sites added9 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
60 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
14th of 31
332 · median 278
Started
2021
with 2 others
Phase 3
17 of 31
1 open now
Registered
25th of 31
by date

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 14th largest by enrollment, is one of 3 that started in 2021, is one of 17 in phase 3, and was the 25th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 60 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate similar efficacy and safety between TVB-009 and Prolia® (denosumab)

Read the detailed description

This is a multinational, multicenter, randomized, double-blind study to demonstrate similar efficacy and safety of TVB-009 compared to Prolia® administered subcutaneously at doses of 60 mg every 26 weeks. Approximately 326 postmenopausal women with osteoporosis will be randomized to receive either TVB-009 or Prolia®. At week 52, patients in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to TVB-009 and receive a single dose of TVB-009 in the transition period to assess immunogenicity and safety after a transition from Prolia® to TVB-009. The total treatment duration for each patient is 78 weeks.

03

Conditions studied

  • Osteoporosis, Postmenopausal
04

Who can participate

Ages eligible
60 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • womeen (≥60 and ≤90 years) with a diagnosis of osteoporosis
  • Body weight ≥50 kg and ≤90 kg
  • Bone Mineral Density (BMD) measurement T score of less than -2.5 but not less than -4.0 by dual-energy X-ray absorptiometry (DXA) at the lumbar spine at screening
  • At least 3 vertebrae in the L1 L4 region that are evaluable by dual-energy X-ray absorptiometry (DXA)

Exclusion criteria

Exclusion Criteria:

  • One severe or more than two moderate vertebral fractures
  • History and/or presence of hip fracture or atypical femur fracture
  • Any prior treatment with denosumab
  • Ongoing use of any bone active drugs which can affect Bone Mineral Density (BMD)
  • Vitamin D deficiency or hyper- or hypocalcemiacium at screening
  • Hyperthyroidism, hypothyroidism, hypoparathyroidism or hyperparathyroidism
  • Any medical condition that could jeopardize or would compromise the patient's safety or ability to participate in this study

Other Inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
332 participants (actual)

Study arms

  • Experimental
    TVB-009 main treatment period

    TVB-009 (denosumab) pre-filled syringe, administered at weeks 1 and 26

    Combination Product: TVB-009

  • Active comparator
    PROLIA main treatment period

    Prolia® (denosumab) pre-filled syringe, administered at weeks 1 and 26

    Combination Product: Prolia®

  • Experimental
    TVB-009 main / TVB-009 transition period

    TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to TVB-009 in the main treatment period

    Combination Product: TVB-009

  • Active comparator
    PROLIA main / PROLIA transition period

    Prolia® (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period

    Combination Product: Prolia®

  • Experimental
    PROLIA main / TVB-009 transition period

    TVB-009 (denosumab) pre-filled syringe, administered at week 52 in patients that were randomized to PROLIA in the main treatment period

    Combination Product: TVB-009 · Combination Product: Prolia®

Interventions

  • Combination productTVB-009

    TVB-009 Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)

  • Combination productDenosumabStudies of DenosumabDenosumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Denosumab solution for injection 60 mg/mL (1 mL) prefilled syringe (PFS)

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in LS-BMD at Week 52

    Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52

    Time frame: Baseline and week 52

Secondary outcomes

  1. Percent Change From Baseline in sCTX-1 at Week 26

    Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen at week 26

    Time frame: Baseline and week 26

  2. Percent Change From Baseline in LS-BMD at Week 26

    Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26

    Time frame: Baseline and week 26

  3. Percent Change From Baseline in Femoral Neck BMD at Week 26

    Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 26

    Time frame: Baseline, week 26

  4. Percent Change From Baseline in Total Hip BMD at Week 26

    Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26

    Time frame: Baseline, week 26

  5. Percent Change From Baseline in sCTX-1

    Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen

    Time frame: Baseline through Week 52

  6. Percentage of Participatns With sCTX-1 Suppression at Week 4

    Proportion of patients with suppression of serum C-telopeptide cross-link of type 1 collagen at week 4

    Time frame: Week 4

  7. Percent Change From Baseline in P1NP

    Percent change from baseline in procollagen type 1 N propeptide (P1NP) to Week 52

    Time frame: Baseline through Week 52

  8. Number of Fractures up to Week 52

    Number of patients with who experienced any new fractures up to week 52.

    Time frame: Up to week 52

  9. Percent Change From Week 52 in LS-BMD by DXA at Week 78

    Percent change from week 52 in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78

    Time frame: Week 52 through week 78

  10. Percent Change From Week 52 in Femoral Neck BMD by DXA at Week 78

    Percent change from week 52 in femoral neck bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78

    Time frame: Week 52 through week 78

  11. Percent Change From Week 52 in Total Hip BMD by DXA at Week 78

    Percent change from week 52 in total hip bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78

    Time frame: Week 52 through week 78

  12. Difference Between Percent Change From Baseline in sCTX-1 Between Week 52 and Week 78

    Difference in the percent change from baseline in serum C-telopeptide cross-link of type 1 collagen from baseline to Week 78 as compared to baseline to Week 52

    Time frame: Baseline, Week 52, Week 78

  13. Difference Between Percent Change From Baseline in P1NP Between Week 52 and Week 78

    The difference in the Percent change from baseline in procollagen type 1 N propeptide at Week 78 compared to Week 52.

    Time frame: Baseline, Week 52, Week 78

  14. Number of Patients With Fractures Between Week 52 and Week 78

    Number of patients experiencing new fractures between week 52 and week 78

    Time frame: Week 52 through week 78

  15. Incidence of Adverse Event

    Number of patients reporting at least one treatment-emergent adverse event up to week 52

    Time frame: Up to week 52

  16. Incidence of Adverse Events in the Transition Period

    Number of patients reporting at least one treatment-emergent adverse event between weeks 52 and 78

    Time frame: Week 52 through week 78

  17. Incidence of Antidrug Antibodies (ADAs) in the Main Treatment Period

    Number of patients with confirmed positive antidrug antibodies (ADAs) post-baseline through Week 52

    Time frame: Anytime Post Baseline through Week 52

  18. Incidence of Antidrug Antibodies (ADAs) in the Transition Period

    Number of patients with confirmed positive antidrug antibodies (ADAs) at Week 65

    Time frame: Anytime in Week 52 through Week 78

  19. Percent Change From Baseline in Femoral Neck BMD at Week 52

    Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 52

    Time frame: Baseline through Week 52

  20. Percent Change From Baseline in Total Hip BMD at Week 52

    Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52

    Time frame: Baseline through Week 52

  21. Number of TEAEs Leading to Patient Withdraw From the Study

    Number of patients that withdraw or are removed from the study due to treatment emergent adverse events from both the main and transition treatment periods.

    Time frame: Main Treatment Period = Baseline-Week 52; Transition period = Week 52-78

  22. Local Tolerability at Injection Site

    Number of patients who report Injection Site Reactions at Day 1, Week 26, or Week 52.

    Time frame: Main Treatment Period = Day 1 & Week 26; Transition Treatment Period = Week 52

07

Results

Posted Apr 18, 2024

Participant flow

Main Treatment Period (Week1 to Week 52)
Participant flow — Main Treatment Period (Week1 to Week 52)
MilestoneTVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Started166166000
Completed148143000
Not completed1823000
Withdrew: Adverse event37000
Withdrew: Withdrawal by subject1312000
Withdrew: Multiple other reasons24000
Transition Period (Week 52 to Week 78)
Participant flow — Transition Period (Week 52 to Week 78)
MilestoneTVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Started001487271
Completed001406769
Not completed00852
Withdrew: Withdrawal by subject00721
Withdrew: Lost to follow-up00010
Withdrew: Multiple other reasons00121

Outcome measures

PrimaryPercent Change From Baseline in LS-BMD at Week 52

Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52

Time frame:
Baseline and week 52
Reported as:
Least squares mean · percentage of change from baseline
Percent Change From Baseline in LS-BMD at Week 52
percentage of change from baselineTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percent Change From Baseline in LS-BMD at Week 524.76 (3.82 to 5.69)4.54 (3.62 to 5.47)
Statistical analysis
  • TVB-009 Main Treatment Period vs PROLIA Main Treatment Period · Mean difference (net): 0.21 · 95% CI -0.73 to 1.15
SecondaryPercent Change From Baseline in sCTX-1 at Week 26

Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen at week 26

Time frame:
Baseline and week 26
Reported as:
Least squares mean · percentage of change from baseline
Percent Change From Baseline in sCTX-1 at Week 26
percentage of change from baselineTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percent Change From Baseline in sCTX-1 at Week 26-56.05 (-64.99 to -47.12)-65.13 (-74.09 to -56.17)
Statistical analysis
  • TVB-009 Main Treatment Period vs PROLIA Main Treatment Period · Mean difference (net): 9.07 · 95% CI -0.14 to 18.29
SecondaryPercent Change From Baseline in LS-BMD at Week 26

Percent change from baseline in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26

Time frame:
Baseline and week 26
Reported as:
Mean · percentage of change from baseline
Percent Change From Baseline in LS-BMD at Week 26
percentage of change from baselineTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percent Change From Baseline in LS-BMD at Week 263.70 ± 4.2943.62 ± 3.815
SecondaryPercent Change From Baseline in Femoral Neck BMD at Week 26

Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 26

Time frame:
Baseline, week 26
Reported as:
Mean · percentage of change from baseline
Percent Change From Baseline in Femoral Neck BMD at Week 26
percentage of change from baselineTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percent Change From Baseline in Femoral Neck BMD at Week 261.87 ± 4.8772.01 ± 3.611
SecondaryPercent Change From Baseline in Total Hip BMD at Week 26

Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 26

Time frame:
Baseline, week 26
Reported as:
Mean · percentage of change from baseline
Percent Change From Baseline in Total Hip BMD at Week 26
percentage of change from baselineTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percent Change From Baseline in Total Hip BMD at Week 261.89 ± 3.4882.02 ± 2.526
SecondaryPercent Change From Baseline in sCTX-1

Percent change from baseline in serum C-telopeptide cross-link of type 1 collagen

Time frame:
Baseline through Week 52
Reported as:
Mean · percentage of change from baseline
Percent Change From Baseline in sCTX-1
percentage of change from baselineTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percent Change From Baseline in sCTX-1-57.91 ± 44.161-68.80 ± 35.846
SecondaryPercentage of Participatns With sCTX-1 Suppression at Week 4

Proportion of patients with suppression of serum C-telopeptide cross-link of type 1 collagen at week 4

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Percentage of Participatns With sCTX-1 Suppression at Week 4
Percentage of participantsTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percentage of Participatns With sCTX-1 Suppression at Week 494.294.0
SecondaryPercent Change From Baseline in P1NP

Percent change from baseline in procollagen type 1 N propeptide (P1NP) to Week 52

Time frame:
Baseline through Week 52
Reported as:
Mean · percentage of change from baseline
Percent Change From Baseline in P1NP
percentage of change from baselineTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percent Change From Baseline in P1NP-56.43 ± 35.431-62.03 ± 33.712
SecondaryNumber of Fractures up to Week 52

Number of patients with who experienced any new fractures up to week 52.

Time frame:
Up to week 52
Reported as:
Number · number participants with fractures
Number of Fractures up to Week 52
number participants with fracturesTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Number of Fractures up to Week 5235
SecondaryPercent Change From Week 52 in LS-BMD by DXA at Week 78

Percent change from week 52 in lumbar spine bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78

Time frame:
Week 52 through week 78
Reported as:
Mean · percentage of change from baseline
Percent Change From Week 52 in LS-BMD by DXA at Week 78
percentage of change from baselineTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Percent Change From Week 52 in LS-BMD by DXA at Week 780.82 ± 3.1201.15 ± 3.4401.24 ± 3.069
SecondaryPercent Change From Week 52 in Femoral Neck BMD by DXA at Week 78

Percent change from week 52 in femoral neck bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78

Time frame:
Week 52 through week 78
Reported as:
Mean · Percent change from week 52
Percent Change From Week 52 in Femoral Neck BMD by DXA at Week 78
Percent change from week 52TVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Percent Change From Week 52 in Femoral Neck BMD by DXA at Week 780.38 ± 3.5250.80 ± 3.5600.94 ± 3.082
SecondaryPercent Change From Week 52 in Total Hip BMD by DXA at Week 78

Percent change from week 52 in total hip bone mineral density (LS BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 78

Time frame:
Week 52 through week 78
Reported as:
Mean · Percent change from week 52
Percent Change From Week 52 in Total Hip BMD by DXA at Week 78
Percent change from week 52TVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Percent Change From Week 52 in Total Hip BMD by DXA at Week 780.01 ± 2.0890.66 ± 2.1090.27 ± 2.264
SecondaryDifference Between Percent Change From Baseline in sCTX-1 Between Week 52 and Week 78

Difference in the percent change from baseline in serum C-telopeptide cross-link of type 1 collagen from baseline to Week 78 as compared to baseline to Week 52

Time frame:
Baseline, Week 52, Week 78
Reported as:
Mean · Percent change from baseline
Difference Between Percent Change From Baseline in sCTX-1 Between Week 52 and Week 78
Percent change from baselineTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Difference Between Percent Change From Baseline in sCTX-1 Between Week 52 and Week 789.95 ± 41.61213.17 ± 28.5587.55 ± 36.509
SecondaryDifference Between Percent Change From Baseline in P1NP Between Week 52 and Week 78

The difference in the Percent change from baseline in procollagen type 1 N propeptide at Week 78 compared to Week 52.

Time frame:
Baseline, Week 52, Week 78
Reported as:
Mean · Percent change
Difference Between Percent Change From Baseline in P1NP Between Week 52 and Week 78
Percent changeTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Difference Between Percent Change From Baseline in P1NP Between Week 52 and Week 783.95 ± 23.3764.83 ± 14.5512.89 ± 39.804
SecondaryNumber of Patients With Fractures Between Week 52 and Week 78

Number of patients experiencing new fractures between week 52 and week 78

Time frame:
Week 52 through week 78
Reported as:
Number · Number participants with fractures
Number of Patients With Fractures Between Week 52 and Week 78
Number participants with fracturesTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Number of Patients With Fractures Between Week 52 and Week 78101
SecondaryIncidence of Adverse Event

Number of patients reporting at least one treatment-emergent adverse event up to week 52

Time frame:
Up to week 52
Reported as:
Count of participants · Participants
Incidence of Adverse Event
ParticipantsTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
TEAE Related to Study Drug1913
TEAE Related to Medical Device00
TEAE Not Related to Study Drug10495
No TEAEs Reported4357
SecondaryIncidence of Adverse Events in the Transition Period

Number of patients reporting at least one treatment-emergent adverse event between weeks 52 and 78

Time frame:
Week 52 through week 78
Reported as:
Count of participants · Participants
Incidence of Adverse Events in the Transition Period
ParticipantsTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
TEAE Related to Study Drug200
TEAE Related to Medical Device000
TEAE Not Related to Study Drug482026
No TEAE Reported985245
SecondaryIncidence of Antidrug Antibodies (ADAs) in the Main Treatment Period

Number of patients with confirmed positive antidrug antibodies (ADAs) post-baseline through Week 52

Time frame:
Anytime Post Baseline through Week 52
Reported as:
Count of participants · Participants
Incidence of Antidrug Antibodies (ADAs) in the Main Treatment Period
ParticipantsTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
ADA Status — Positive1125
ADA Status — Positive, Not Treatment Related811
ADA Status — Negative147129
Neutralizing ADA Status Among Positive — Positive12
Neutralizing ADA Status Among Positive — Positive, Not Treatment Related00
Neutralizing ADA Status Among Positive — Negative1023
SecondaryIncidence of Antidrug Antibodies (ADAs) in the Transition Period

Number of patients with confirmed positive antidrug antibodies (ADAs) at Week 65

Time frame:
Anytime in Week 52 through Week 78
Reported as:
Count of participants · Participants
Incidence of Antidrug Antibodies (ADAs) in the Transition Period
ParticipantsTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
ADA Status — Positive754
ADA Status — Positive, Not Treatment Related741
ADA Status — Negative1336165
Neutralizing ADA Status Among Positive — Positive100
Neutralizing ADA Status Among Positive — Positive, Not Treatment Related000
Neutralizing ADA Status Among Positive — Negative654
SecondaryPercent Change From Baseline in Femoral Neck BMD at Week 52

Percent change from baseline in femoral neck bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA)at week 52

Time frame:
Baseline through Week 52
Reported as:
Mean · Percent change from baseline
Percent Change From Baseline in Femoral Neck BMD at Week 52
Percent change from baselineTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percent Change From Baseline in Femoral Neck BMD at Week 522.39 ± 5.7952.34 ± 3.780
SecondaryPercent Change From Baseline in Total Hip BMD at Week 52

Percent change from baseline in total hip bone mineral density (BMD) based on centrally assessed dual energy X ray absorptiometry (DXA) at week 52

Time frame:
Baseline through Week 52
Reported as:
Mean · Percent change from baseline
Percent Change From Baseline in Total Hip BMD at Week 52
Percent change from baselineTVB-009 Main Treatment PeriodPROLIA Main Treatment Period
Percent Change From Baseline in Total Hip BMD at Week 522.67 ± 3.9813.00 ± 2.768
SecondaryNumber of TEAEs Leading to Patient Withdraw From the Study

Number of patients that withdraw or are removed from the study due to treatment emergent adverse events from both the main and transition treatment periods.

Time frame:
Main Treatment Period = Baseline-Week 52; Transition period = Week 52-78
Reported as:
Count of participants · Participants
Number of TEAEs Leading to Patient Withdraw From the Study
ParticipantsTVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Number of TEAEs Leading to Patient Withdraw From the Study37000
SecondaryLocal Tolerability at Injection Site

Number of patients who report Injection Site Reactions at Day 1, Week 26, or Week 52.

Time frame:
Main Treatment Period = Day 1 & Week 26; Transition Treatment Period = Week 52
Reported as:
Count of participants · Participants
Local Tolerability at Injection Site
ParticipantsTVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Day 1 — Erythema54———
Day 1 — Ecchymosis42———
Day 1 — Induration23———
Day 1 — Tenderness34———
Day 1 — Warmth01———
Day 1 — Swelling21———
Day 1 — Pain65———
Day 1 — No Reaction144145———
Week 26 — Erythema24———
Week 26 — Ecchymosis30———
Week 26 — Induration20———
Week 26 — Tenderness11———
Week 26 — Warmth01———
Week 26 — Swelling11———
Week 26 — Pain74———
Week 26 — No Reaction142142———
Week 52 — Erythema——222
Week 52 — Ecchymosis——301
Week 52 — Induration——330
Week 52 — Tenderness——111
Week 52 — Warmth——020
Week 52 — Swelling——011
Week 52 — Pain——643
Week 52 — No Reaction——1335963

Adverse events

Collected over The Main Treatment Period collected adverse event data for a 52 week period (baseline to week 52). The transitional period collected adverse event data for a 26 week period (week 52 to week 78).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TVB-009 Main Treatment Period0/166 (0%)8/166 (4.8%)123/166 (74.1%)
PROLIA Main Treatment Period0/165 (0%)6/165 (3.6%)108/165 (65.5%)
TVB-009 Main / TVB-009 Transition Period0/148 (0%)5/148 (3.4%)42/148 (28.4%)
PROLIA Main / PROLIA Transition Period0/72 (0%)0/72 (0%)20/72 (27.8%)
PROLIA Main / TVB-009 Transition Period0/71 (0%)1/71 (1.4%)11/71 (15.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventTVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
CholelithiasisHepatobiliary disorders1/1660/1650/1480/721/71
COVID-19 pneumoniaInfections and infestations0/1661/1651/1480/720/71
MalaiseGeneral disorders0/1660/1651/1480/720/71
Helicobacter infectionInfections and infestations0/1660/1651/1480/720/71
Bone cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1660/1651/1480/720/71
Urinary incontinenceRenal and urinary disorders0/1660/1651/1480/720/71
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/1660/1651/1480/720/71
Atrial flutterCardiac disorders0/1661/1650/1480/720/71
Myocardial ischaemiaCardiac disorders0/1661/1650/1480/720/71
Cholecystitis acuteHepatobiliary disorders0/1661/1650/1480/720/71
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTVB-009 Main / TVB-009 Transition PeriodPROLIA Main / PROLIA Transition PeriodPROLIA Main / TVB-009 Transition Period
Vitamin D deficiencyMetabolism and nutrition disorders34/16621/1652/1480/720/71
COVID-19Infections and infestations17/16622/1653/1480/721/71
HypercalcaemiaMetabolism and nutrition disorders14/16619/1654/1482/722/71
HeadacheNervous system disorders16/16615/1654/1481/723/71
ArthralgiaMusculoskeletal and connective tissue disorders14/16613/1654/1484/720/71
NasopharyngitisInfections and infestations7/1669/1654/1485/720/71
Pain in extremityMusculoskeletal and connective tissue disorders6/16610/1653/1483/720/71
Vitamin D decreasedInvestigations10/1665/1650/1480/721/71
Back painMusculoskeletal and connective tissue disorders9/1666/1658/1482/720/71
HypertensionVascular disorders8/1668/1651/1480/720/71

Baseline characteristics

The baseline characteristics are only presented for the Treatment Period Arms as the same subject were employed in the Transition Period.

Age, Continuous
Age, Continuous(years)TVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTotal
Mean68.5 ± 5.6967.7 ± 5.5668.1 ± 5.63
Sex: Female, Male
Sex: Female, Male(Participants)TVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTotal
Female166166332
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTotal
Hispanic or Latino231841
Not Hispanic or Latino143148291
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American112
White165164329
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(participants)TVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTotal
Hungary11617
United States343569
Czechia211940
Ukraine131225
Poland303767
Georgia17926
Slovakia61319
Bulgaria222042
Germany112
Russia111425
Previous Use of Biophosphonates
Previous Use of Biophosphonates(Participants)TVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTotal
Yes212142
No145145290
Prior Fractures
Prior Fractures(Participants)TVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTotal
Yes373875
No129128257
Taking Calcium & Vitamin D Supplements
Taking Calcium & Vitamin D Supplements(Participants)TVB-009 Main Treatment PeriodPROLIA Main Treatment PeriodTotal
Yes282856
No91019
08

Study locations

78 sites
  • Teva Site 103
    Phoenix, Arizona 85004, United States
  • Teva Site 119
    Tucson, Arizona 85704, United States
  • Teva Site 118
    San Diego, California 92111, United States
  • Teva Site 107
    New London, Connecticut 06320, United States
  • Teva Site 115
    Coral Gables, Florida 33134, United States
  • Teva Site 114
    Edgewater, Florida 32132, United States
  • Teva Site 116
    Lake City, Florida 32055, United States
  • Teva Site 109
    Miami Lakes, Florida 33014, United States
  • Teva Site 117
    Miami Springs, Florida 33166, United States
  • Teva Site 110
    Oldsmar, Florida 34677, United States
  • Teva Site 120
    Orlando, Florida 32801, United States
  • Teva Site 102
    Ormond Beach, Florida 32174, United States
  • Teva Site 101
    Port Saint Lucie, Florida 34952, United States
  • Teva Site 111
    Sarasota, Florida 34239, United States
  • Teva Site 104
    Tamarac, Florida 33321, United States
  • Teva Site 112
    Henderson, Nevada 89014, United States
  • Teva Site 113
    North Las Vegas, Nevada 89030, United States
  • Teva Site 105
    Albuquerque, New Mexico 87106, United States
  • Teva Site 108
    Duncansville, Pennsylvania 16635, United States
  • Teva Site 106
    Seattle, Washington 98105, United States
  • Teva Site 203
    Blagoevgrad, Bulgaria
  • Teva Site 207
    Dimitrovgrad, Bulgaria
  • Teva Site 252
    Haskovo, Bulgaria
  • Teva Site 202
    Lom, Bulgaria
  • Teva Site 205
    Plovdiv, Bulgaria
  • Teva Site 250
    Silistra, Bulgaria
  • Teva Site 201
    Sofia, Bulgaria
  • Teva Site 204
    Sofia, Bulgaria
  • Teva Site 251
    Sofia, Bulgaria
  • Teva Site 206
    Stara Zagora, Bulgaria
  • Teva Site 211
    Brno, Czechia
  • Teva Site 213
    Ostrava, Czechia
  • Teva Site 212
    Pardubice, Czechia
  • Teva Site 209
    Prague, Czechia
  • Teva Site 210
    Prague, Czechia
  • Teva Site 208
    Uherské Hradiště, Czechia
  • Teva Site 214
    Tbilisi, Georgia
  • Teva Site 215
    Tbilisi, Georgia
  • Teva Site 216
    Tbilisi, Georgia
  • Teva Site 217
    Tbilisi, Georgia
  • Teva Site 218
    Tbilisi, Georgia
  • Teva Site 219
    Tbilisi, Georgia
  • Teva Site 223
    Dresden, Germany
  • Teva Site 220
    Hamburg, Germany
  • Teva Site 221
    Nümbrecht, Germany
  • Teva Site 222
    Würzburg, Germany
  • Teva Site 226
    Balatonfüred, Hungary
  • Teva Site 225
    Budapest, Hungary
  • Teva Site 227
    Budapest, Hungary
  • Teva Site 253
    Budapest, Hungary
  • Teva Site 224
    Nyíregyháza, Hungary
  • Teva Site 228
    Bialystok, Poland
  • Teva Site 233
    Krakow, Poland
  • Teva Site 231
    Lodz, Poland
  • Teva Site 230
    Warsaw, Poland
  • Teva Site 232
    Warsaw, Poland
  • Teva Site 229
    Wroclaw, Poland
  • Teva Site 235
    Moscow, Russia
  • Teva Site 236
    Saint Petersburg, Russia
  • Teva Site 254
    Saint Petersburg, Russia
  • Teva Site 255
    Saint Petersburg, Russia
  • Teva Site 256
    Saint Petersburg, Russia
  • Teva Site 257
    Saint Petersburg, Russia
  • Teva Site 234
    Yaroslavl, Russia
  • Teva Site 258
    Yaroslavl, Russia
  • Teva Site 238
    Bratislava, Slovakia
  • Teva Site 242
    Bratislava, Slovakia
  • Teva Site 237
    Hlohovec, Slovakia
  • Teva Site 241
    Lučenec, Slovakia
  • Teva Site 240
    Ľubochňa, Slovakia
  • Teva Site 239
    Prešov, Slovakia
  • Teva Site 244
    Kyiv, Ukraine
  • Teva Site 245
    Kyiv, Ukraine
  • Teva Site 247
    Kyiv, Ukraine
  • Teva Site 248
    Kyiv, Ukraine
  • Teva Site 249
    Kyiv, Ukraine
  • Teva Site 243
    Vinnytsia, Ukraine
  • Teva Site 246
    Zaporizhia, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Dec 2022, 21 months.

Results were first posted in Apr 2024, 1 year 3 months after primary completion.

Of 29 industry-sponsored phase 3 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 43. This study's 21 months is below that.

Counting every sponsor, half of 30 studies reached it within 24 months; a quarter within 20 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2021
First posted
Jan 28, 2021
StartActual
Mar 22, 2021
Primary completionActual
Dec 31, 2022
CompletionActual
Jun 19, 2023
Results first posted
Apr 18, 2024
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
9 sites added, 9 sites removed
Show 9 added (4 Poland, 2 Czechia, 1 Germany, 1 Hungary, 1 Slovakia)
  • Teva Site 209 · Prague, Czechia
  • Teva Site 210 · Prague, Czechia
  • Teva Site 221 · Nümbrecht, Germany
  • Teva Site 224 · Nyíregyháza, Hungary
  • Teva Site 228 · Bialystok, Poland
  • Teva Site 233 · Krakow, Poland
  • Teva Site 231 · Lodz, Poland
  • Teva Site 229 · Wroclaw, Poland
  • Teva Site 240 · Ľubochňa, Slovakia
Show 9 removed
  • Teva Site 209 · Praha, Czechia
  • Teva Site 210 · Praha, Czechia
  • Teva Site 221 · Numbrecht, Germany
  • Teva Site 224 · Nyiregyhaza, Hungary
  • Teva Site 228 · Białystok, Poland
  • Teva Site 233 · Kraków, Poland
  • Teva Site 229 · Wrocław, Poland
  • Teva Site 231 · Łódź, Poland
  • Teva Site 240 · Lubochna, Slovakia
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    9 sites added, 9 sites removed
    Show 9 added (4 Poland, 2 Czechia, 1 Germany, 1 Hungary, 1 Slovakia)
    • Teva Site 209 · Prague, Czechia
    • Teva Site 210 · Prague, Czechia
    • Teva Site 221 · Nümbrecht, Germany
    • Teva Site 224 · Nyíregyháza, Hungary
    • Teva Site 228 · Bialystok, Poland
    • Teva Site 233 · Krakow, Poland
    • Teva Site 231 · Lodz, Poland
    • Teva Site 229 · Wroclaw, Poland
    • Teva Site 240 · Ľubochňa, Slovakia
    Show 9 removed
    • Teva Site 209 · Praha, Czechia
    • Teva Site 210 · Praha, Czechia
    • Teva Site 221 · Numbrecht, Germany
    • Teva Site 224 · Nyiregyhaza, Hungary
    • Teva Site 228 · Białystok, Poland
    • Teva Site 233 · Kraków, Poland
    • Teva Site 229 · Wrocław, Poland
    • Teva Site 231 · Łódź, Poland
    • Teva Site 240 · Lubochna, Slovakia
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04729621
Responsible party
Sponsor
First posted
Jan 28, 2021
Start date
Mar 22, 2021
Primary completion
Dec 31, 2022
Completion
Jun 19, 2023
Results posted
Apr 18, 2024
Last update
Oct 1, 2026

Study contacts

Teva Medical Expert, MD
study director · Teva Pharmaceuticals, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion